Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.57 |
| ▸ | SRC | P12931 | 18/20 | 0.57 |
| ▸ | SYK | P43405 | 17/20 | 0.57 |
| ▸ | GSK3A | P49840 | 12/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298583 | 0.92 | MAPK14 (0.54) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6643563 | 0.91 | GSK3A (0.62) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6299897 | 0.91 | MAPK14 (0.52) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6304947 | 0.91 | SRC (0.49) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6298574 | 0.88 | GSK3A (0.57) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6306246 | 0.88 | GSK3A (0.51) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6305628 | 0.87 | GSK3A (0.53) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6305886 | 0.86 | GSK3A (0.54) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6298627 | 0.85 | GSK3A (0.51) | MAPK14SRCSYKGSK3A | |
| SCHEMBL6546731 | 0.83 | MAPK14 (0.51) | MAPK14SRCSYKGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | claimed |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | US | claimed |
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1392661-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002092576-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | TNF, MPO, PTGES | MAPK14 2714/4885SRC 3231/4885SYK 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.